Delisting extension and massive warrant dilution for Bluejay Diagnostics (BJDX); authorized shares up to 250M

Bluejay Diagnostics, Inc.

Nasdaq extended compliance deadline to Feb 24, 2025; stock must close at $1.00+ for 10 days.
Stockholders approved increase in authorized common shares from 50M to 250M.
Class D warrants exercisable for ~21.5M shares at $0.0001; 6.6M shares issued so far.
Class C warrants exercise price reset from $1.96 to $0.326, increasing potential dilution.
Outstanding shares as of Aug 27: 12.85M; significant dilution expected from warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.